Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 2 Lymphoma, Large B-Cell, Diffuse 2 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Multiple Myeloma 1 Leukemia 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 361 Pemetrexed 276 Cisplatin 230 Paclitaxel 213 Docetaxel 205 Gemcitabine 160 Erlotinib Hydrochloride 150 Bevacizumab 132 pembrolizumab 129 Radiotherapy 114 Nivolumab 88 durvalumab 84 Drug Therapy 84 osimertinib 82 atezolizumab 58 Vinorelbine 53 Gefitinib 53 Radiosurgery 50 Cetuximab 39 Taxes 37 130-nm albumin-bound paclitaxel 36 Ipilimumab 34 anlotinib 33 Surgical Procedures, Operative 33 Magnetic Resonance Spectroscopy 33 Etoposide 30 Albumin-Bound Paclitaxel 29 tislelizumab 27 icotinib 27 aflutinib 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Non-Small-Cell Lung × HBI-8000 × Clear all

NCT05141357 2025-12-24

HBI-8000

HUYABIO International, LLC.

Phase 2 Terminated

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡